Biogen (BIIB) Change in Receivables (2009 - 2026)
Biogen (BIIB) posted quarterly Change in Receivables of $269.4 million for Q2 2026, up 2665.71% year-over-year from $9.7 million in Q2 2025, and up 360.54% quarter-over-quarter from -$103.4 million in Q1 2026.
Biogen (BIIB) Change in Receivables (2009 - 2026) Analysis & Trends
Biogen's Change in Receivables history runs 18 years deep, the most recent figure standing at $269.4 million for Q2 2026.
- In Q2 2026, Change in Receivables rose 2665.71% year-over-year to $269.4 million; the TTM figure through Jun 2026 stood at -$107.2 million (down 60.24% YoY), while the FY2025 annual figure was -$102.7 million, up 53.8% from the prior year.
- Change in Receivables for Q2 2026 stood at $269.4 million, up from -$103.4 million in the prior quarter.
- The five-year high for Change in Receivables was $269.4 million in Q2 2026, with the low at -$245.4 million in Q3 2025.
- The 5-year median for Change in Receivables is -$15.4 million (2022), against an average of -$938888.9.
- The sharpest annual moves came in 2023 and 2026: Change in Receivables slumped 246.75% in 2023, then soared 2665.71% in 2026.
- Biogen's Change in Receivables stood at $93.9 million in 2022, then plunged by 246.75% to -$137.8 million in 2023, then jumped by 31.28% to -$94.7 million in 2024, then soared by 70.64% to -$27.8 million in 2025, then surged by 1069.06% to $269.4 million in 2026.
- Business Quant data shows BIIB's Change in Receivables at $269.4 million in Q2 2026, -$103.4 million in Q1 2026, and -$27.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.09 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 333.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 269.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 269.40 Mn |
| Jun 30, 2026 | 269.40 Mn |
| Mar 31, 2026 | -103.40 Mn |
| Mar 31, 2026 | -103.40 Mn |
| Dec 31, 2025 | -27.80 Mn |
| Dec 31, 2025 | -27.80 Mn |
| Sep 30, 2025 | -245.40 Mn |
| Sep 30, 2025 | -245.40 Mn |
| Jun 30, 2025 | -10.50 Mn |
| Jun 30, 2025 | -10.50 Mn |
| Mar 31, 2025 | 181.00 Mn |
| Mar 31, 2025 | 181.00 Mn |
| Dec 31, 2024 | -94.70 Mn |
| Dec 31, 2024 | -94.70 Mn |
| Sep 30, 2024 | -142.70 Mn |
| Sep 30, 2024 | -142.70 Mn |
| Jun 30, 2024 | 58.80 Mn |
| Jun 30, 2024 | 58.80 Mn |
| Mar 31, 2024 | -43.70 Mn |
| Mar 31, 2024 | -43.70 Mn |